UK markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8800+0.6000 (+26.32%)
At close: 04:00PM EST
2.7100 -0.17 (-5.90%)
After hours: 04:43PM EST

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
972 3 541 3131

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees113

Key executives

NameTitlePayExercisedYear born
Mr. Dror Ben-AsherCo-Founder, CEO & Director734.59kN/A1966
Mr. Gilead Raday MPhil, MScChief Operating Officer445.38kN/A1975
Mr. Adi FrishChief Corporate & Business Development Officer419.5kN/A1970
Mr. Rick D. ScruggsChief Commercial Officer, President of RedHill Biopharma Inc. & Director607.05kN/A1960
Mr. Razi IngberChief Financial OfficerN/AN/A1984
Ms. Alexandra OkmianSenior Business Development & Investor Relations ManagerN/AN/AN/A
Dr. Reza Fathi Ph.D.Senior Vice President of Research & Development299.29kN/A1955
Mr. Guy GoldbergChief Business Officer338.13kN/A1976
Dr. June S. Almenoff FACP, M.D., Ph.D.Chief Medical OfficerN/AN/A1957
Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Corporate governance

RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.